Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time.

Heald A, Livingston M, Yung A, De Hert MA.

Hum Psychopharmacol. 2017 Mar;32(2). doi: 10.1002/hup.2579.

PMID:
28370308
2.

Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole.

Jakobsen KD, Bruhn CH, Pagsberg AK, Fink-Jensen A, Nielsen J.

J Clin Psychopharmacol. 2016 Oct;36(5):496-9. doi: 10.1097/JCP.0000000000000548.

PMID:
27504593
3.

Dexamethasone-induced catatonia in a patient with multiple myeloma.

Vanstechelman S, Vantilborgh A, Lemmens G.

Acta Clin Belg. 2016 Dec;71(6):438-440. Epub 2016 Apr 28.

PMID:
27121754
4.

Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.

Barnes TR, Leeson VC, Paton C, Costelloe C, Simon J, Kiss N, Osborn D, Killaspy H, Craig TK, Lewis S, Keown P, Ismail S, Crawford M, Baldwin D, Lewis G, Geddes J, Kumar M, Pathak R, Taylor S.

Health Technol Assess. 2016 Apr;20(29):1-46. doi: 10.3310/hta20290.

5.

A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.

Gaviria AM, Franco JG, Aguado V, Rico G, Labad J, de Pablo J, Vilella E.

PLoS One. 2015 Oct 1;10(10):e0139403. doi: 10.1371/journal.pone.0139403. eCollection 2015.

6.

Gender differences in antipsychotics prescribed to veterans with serious mental illness.

Schwartz E, Charlotte M, Slade E, Medoff D, Li L, Dixon L, Kilbourne A, Kreyenbuhl J.

Gen Hosp Psychiatry. 2015 Jul-Aug;37(4):347-51. doi: 10.1016/j.genhosppsych.2015.03.018. Epub 2015 Apr 1.

PMID:
25936673
7.

The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics.

Berndt ER, Gibbons RS, Kolotilin A, Taub AL.

J Health Econ. 2015 Mar;40:26-39. doi: 10.1016/j.jhealeco.2014.11.003. Epub 2014 Dec 12.

PMID:
25575344
8.
9.

Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.

Moritz S, Hünsche A, Lincoln TM.

Eur Neuropsychopharmacol. 2014 Nov;24(11):1745-52. doi: 10.1016/j.euroneuro.2014.09.008. Epub 2014 Sep 16.

PMID:
25444234
10.

California State Hospital Violence Assessment and Treatment (Cal-VAT) guideline.

Stahl SM, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S, Warburton K.

CNS Spectr. 2014 Oct;19(5):449-65.

PMID:
27358935
11.

Checking the plausibility of psychiatrists׳ arguments for not prescribing depot medication.

Hamann J, Kissling W, Heres S.

Eur Neuropsychopharmacol. 2014 Sep;24(9):1506-10. doi: 10.1016/j.euroneuro.2014.06.015. Epub 2014 Jul 4.

PMID:
25037772
12.

A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia.

Potkin SG, Bera R, Eramo A, Lau G.

Clin Schizophr Relat Psychoses. Winter 2017;10(4):211-221. doi: 10.3371/CSRP.PORI.050614. Epub 2014 May 20.

PMID:
24846880
13.

[Antipsychotic prescription patterns in patients affiliated to the Social Security Health System in Colombia].

Machado-Alba JE, Morales-Plaza CD.

Biomedica. 2013 Jul-Sep;33(3):418-28. Spanish.

14.

Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012.

Bachmann CJ, Lempp T, Glaeske G, Hoffmann F.

Dtsch Arztebl Int. 2014 Jan 17;111(3):25-34. doi: 10.3238/arztebl.2014.0025.

15.
16.

Venlafaxine abuse in a patient with schizophrenia and prior history of substance dependence: a case report.

Namdari B.

J Addict Dis. 2013;32(4):393-5. doi: 10.1080/10550887.2013.849974.

PMID:
24325773
17.

Psychopharmacotherapy prescription and suicidal behaviour.

Jagodic HK, Agius M, Pregelj P.

Psychiatr Danub. 2013 Sep;25 Suppl 2:S324-8. Review.

18.

Money matters: does the reimbursement policy for second generation antipsychotics influence the number of recorded schizophrenia patients and the burden of stigmatization?

Kiejna A, Misiak B, Zagdanska M, Drapala J, Piotrowski P, Szczesniak D, Chladzinska-Kiejna S, Cialkowska-Kuzminska M, Frydecka D.

Soc Psychiatry Psychiatr Epidemiol. 2014 Apr;49(4):531-9.

19.

Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.

Crespo-Facorro B, de la Foz VO, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Martinez-Garcia O, Pérez-Iglesias R.

Psychopharmacology (Berl). 2014 Jan;231(2):357-66.

PMID:
23958945
20.

A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.

Iyer S, Banks N, Roy MA, Tibbo P, Williams R, Manchanda R, Chue P, Malla A.

Can J Psychiatry. 2013 May;58(5 Suppl 1):23S-9S.

PMID:
23945064

Supplemental Content

Loading ...
Support Center